CorMedix enters into 5-year agreement with ARC Dialysis

• CorMedix (NASDAQ:CRMD) said on Monday it had entered into a 5-year commercial supply contract with Florida-based dialysis provider, ARC Dialysis, for the supply of DefenCath (taurolidine and heparin).
• CRMD expects to begin the commercialization of DefenCath in the inpatient setting on April 15th.
• Press Release

More on CorMedix

• CorMedix (CRMD) Q4 2023 Earnings Call Transcript
• Seeking Alpha’s Quant Rating on CorMedix
• Historical earnings data for CorMedix
• Financial information for CorMedix